Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Clinical translation of radiotheranostics for precision oncology

Nature Reviews Bioengineering volume 1, pages 612–614 (2023)Cite this article

Subjects

Radiotheranostics combines disease-specific molecular imaging and radionuclide therapy. We present new and promising targets, tracers and isotopes for radiotheranostics and outline the road to clinical translation of the 177Lu–LNC1004 radiopharmaceutical, which has recently been approved by the US Food and Drug Administration (FDA) for a phase I clinical trial.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bodei, L., Herrmann, K., Schöder, H., Scott, A. M. & Lewis, J. S. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat. Rev. Clin. Oncol. 19, 534–550 (2022).

    Article  Google Scholar 

  2. Herrmann, K. et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 21, e146–e156 (2020).

    Article  Google Scholar 

  3. Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).

    Article  Google Scholar 

  4. Fanti, S. et al. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol. 19, E696–E708 (2018).

    Article  Google Scholar 

  5. Dolgin, E. Radioactive drugs emerge from the shadows to storm the market. Nat. Biotechnol. 36, 1125–1127 (2018).

    Article  Google Scholar 

  6. Bauer, D., Sarrett, S. M., Lewis, J. S. & Zeglis, B. M. Click chemistry: a transformative technology in nuclear medicine. Nat. Protoc. 18, 1659–1668 (2023).

    Article  Google Scholar 

  7. Sartor, O. et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).

    Article  Google Scholar 

  8. Zhang, J. et al. From bench to bedside-the Bad Berka experience with first-in-human studies. Semin. Nucl. Med. 49, 422–437 (2019).

    Article  Google Scholar 

  9. Strosberg, J. R. et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 1752–1763 (2021).

    Article  Google Scholar 

  10. Wen, X. et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics 12, 422–433 (2022).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    Jingjing Zhang, Tianzhi Zhao, Vivianne Jakobsson & Xiaoyuan Chen

  2. Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    Jingjing Zhang, Tianzhi Zhao, Vivianne Jakobsson & Xiaoyuan Chen

  3. Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    Jingjing Zhang, Tianzhi Zhao, Vivianne Jakobsson & Xiaoyuan Chen

  4. Department of Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore, Singapore

    Xiaoyuan Chen

  5. Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), Singapore, Singapore

    Xiaoyuan Chen

Authors
  1. Jingjing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tianzhi Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vivianne Jakobsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoyuan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jingjing Zhang or Xiaoyuan Chen.

Ethics declarations

Competing interests

X.C. is the co-founder and CTO of Yantai LNC Biotechnology. J.Z. is the CMO of Yantai LNC Biotechnology. The other authors declare no competing interests.

Additional information

Related links

US $5.32 billion in 2022 with a compound annual growth rate of about 10.7% to reach US $12.18 billion by 2030: https://www.databridgemarketresearch.com/reports/global-radiopharmaceuticals-market

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, J., Zhao, T., Jakobsson, V. et al. Clinical translation of radiotheranostics for precision oncology. Nat Rev Bioeng 1, 612–614 (2023). https://doi.org/10.1038/s44222-023-00106-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44222-023-00106-9

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research